Immatics N.V. (NASDAQ: IMTX)
$12.44
-0.1100 ( -0.88% ) 51.5K
Immatics NV is a biotechnology company that is engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies.
Market Data
Open
$12.44
Previous close
$12.55
Volume
51.5K
Market cap
$1.28B
Day range
$12.35 - $13.37
52 week range
$7.15 - $13.77
SEC Fillings
| Form Type | Description | Pages | Date |
|---|---|---|---|
| 6-k | Quarterly Reports | 2 | Jun 20, 2024 |
| 6-k | Quarterly Reports | 7 | Jun 03, 2024 |
| 6-k | Quarterly Reports | 75 | May 14, 2024 |
| 20-f | Annual reports | 155 | Mar 21, 2024 |
| 6-k | Quarterly Reports | 78 | Mar 21, 2024 |
| 6-k | Quarterly Reports | 83 | Jan 22, 2024 |
| 6-k | Quarterly Reports | 4 | Nov 14, 2023 |
| 6-k | Quarterly Reports | 141 | Nov 08, 2023 |
| 6-k | Quarterly Reports | 4 | Oct 24, 2023 |
| 6-k | Quarterly Reports | 77 | Sep 11, 2023 |